California stem cell biotech, StemCells, Inc. ($STEM), has really struggled for years and its stock is now flatlining raising the question: can it cheat death? Will 2016 be the year that STEM turns things around? So far this year hasn’t started off that well. You can see the graph at right from today on the STEM stock price. Ron Leuty over at San Francisco Business Times reported a couple of weeks ago on a juicy severance package for departing STEM CEO Marty McGlynn despite …Read More
The annual ISSCR meeting has started in Stockholm. This is always a great annual meeting both for the science and for connecting with people including new friends and colleagues as well as old friends. Another element to the meeting is the insider conversations in the halls, restaurants, and bars that tell a behind the scenes story of the stem cell field. Below are my top 10 things to look for that might be discussed over a beer or coffee this year. Also be sure to check …Read More
In my book, Stem Cells: An Insider’s Guide, I have published something new for the stem cell field: a Stem Cell Patients Bill of Rights. I’ve past it below in visual form. As I was making this Bill of Rights, I thought about what patients have told me are the most pressing issues for them as they considering stem cell treatments. I also have done years of research on the most important clinical issues related to the use of stem cells.
Total Stem Cell Clinical TrialsLate in 2012 I did a piece on the global trends in stem cell clinical trials. It is time for an update. Another look at stem cell clinical trials now (late Sept. 2013) based on the clinicaltrials.gov database shows an encouraging trend. Total Stem Cell Clinical Trials The total number of stem cell clinical trials registered in the database has risen in the last 10 months or so from 4,316 to 4,775, a 10.6% increase. The U.S. continues to dominate …Read More
This is the first in a new series of posts I’m doing in lessons I’ve learned from the ever-increasing number of patients who contact me directly or are readers of this blog who make great comments. Today’s post is focused on the lack of availability of and exclusions of the vast majority of patients from clinical trials, an issue that I believe many stem cell researchers are largely unaware of at this time. The standard advice in the stem cell field is to encourage …Read More